Pre-Made Ramatercept Biosimilar, Fusion Protein targeting MSTN/GDF-8 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting GDF8/MSLHP is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ramatercept is a fusion protein of activin receptor type IIB and IgG1-Fc, which binds myostatin and related ligands. It aims to disrupt the inhibitory effect on muscle development and provide potential therapy for myopathies like Duchenne muscular dystrophy (DMD).